指南与共识炎症性肠病

美国专家共识:标准化炎症性肠病肠外表现的定义、随访和治疗目标

A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
指南 / 共识 · Aliment Pharmacol Ther · 2022-03-11

该共识由12名消化内科医生、4名风湿科医生、3名眼科医生、6名皮肤科医生和4名患者代表组成的跨学科专家组,采用改良德尔菲法对54个候选条目进行三轮投票,针对结节性红斑、坏疽性脓皮病、葡萄膜炎、外周关节炎和中轴关节炎五种肠外表现,制定了定义、诊断与管理的合适亚专科医生、疾病监测方法、监测间隔以及缓解和复发的定义。

要点

  • 共识采用改良德尔菲法,三轮投票制定五种肠外表现的定义与监测方法。
  • 明确了每种肠外表现应由哪些亚专科医生进行诊断和管理。
  • 监测选项包括患者报告结局和医生报告结局。

核心结论

  • 针对五种肠外表现的适当和最佳诊断与监测方法已制定共识标准,作为指导临床实践和未来试验设计的起点。

研究设计与样本

  • 由12名消化内科医生、4名风湿科医生、3名眼科医生、6名皮肤科医生和4名患者代表组成的跨学科专家组,采用改良德尔菲共识方法,对源自文献综述和专家意见的54个候选条目进行三轮投票。

主要发现

  • 专家组为结节性红斑、坏疽性脓皮病、葡萄膜炎、外周关节炎和中轴关节炎制定了定义。
  • 专家组确定了诊断和管理每种肠外表现的适当和最佳亚专科医生。
  • 专家组提供了监测疾病进程的方法,并给出了监测间隔的指导。
  • 专家组定义了缓解和复发。
  • 关键发现包括直接的诊断标准、关于谁能适当和最佳诊断每种肠外表现的指导,以及包括患者和医生报告结局的监测选项。

关键数值与推荐

  • 原文未报告具体推荐等级或强度标签。

临床怎么用

  • 这些发现将用于全国多中心研究网络,以优化肠外表现的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. METHODS: As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. RESULTS: For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. CONCLUSIONS: Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Falloon K, Cohen B, Ananthakrishnan AN, et al. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35277863. doi:10.1111/apt.16853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。